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Asthma reduces glioma formation by T cell
decorin-mediated inhibition of microglia
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Jit Chatterjee1, Shilpa Sanapala1, Olivia Cobb1, Alice Bewley1, Andrea K. Goldstein1, Elizabeth Cordell1, Xia Ge2,
Joel R. Garbow2, Michael J. Holtzman 3 & David H. Gutmann 1 ✉

To elucidate the mechanisms underlying the reduced incidence of brain tumors in children
with Neuroﬁbromatosis type 1 (NF1) and asthma, we leverage Nf1 optic pathway glioma
(Nf1OPG) mice, human and mouse RNAseq data, and two different experimental asthma
models. Following ovalbumin or house dust mite asthma induction at 4–6 weeks of age
(WOA), Nf1OPG mouse optic nerve volumes and proliferation are decreased at 12 and 24
WOA, indicating no tumor development. This inhibition is accompanied by reduced
expression of the microglia-produced optic glioma mitogen, Ccl5. Human and murine T cell
transcriptome analyses reveal that inhibition of microglia Ccl5 production results from
increased T cell expression of decorin, which blocks Ccl4-mediated microglia Ccl5 expression
through reduced microglia NFκB signaling. Decorin or NFκB inhibitor treatment of Nf1OPG
mice at 4–6 WOA inhibits tumor formation at 12 WOA, thus establishing a potential
mechanistic etiology for the attenuated glioma incidence observed in children with asthma.
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rior case-controlled clinical studies have revealed a reduced
incidence of brain tumors in children with T-cell-mediated
disorders, including asthma1–4. Similarly, in the Neuroﬁbromatosis type 1 (NF1) brain cancer predisposition, we previously reported an inverse association between asthma and optic
gliomas, the most common brain tumor in this population of atrisk children5. To study this inverse association between asthma
and brain tumor incidence in a cancer predisposition syndrome
in which atopic conditions reduce glioma incidence, we leveraged
a genetically engineered mouse model of NF1-low-grade glioma
of the optic pathway. This authenticated preclinical murine model
exhibits high tumor penetrance (>95%) and a well-characterized
temporal course of glioma progression6,7. As such, Nf1ﬂox/mut;
GFAP-Cre (Nf1OPG) mice develop low-grade gliomas of the optic
nerves and chiasm by 12 weeks of age, with accompanying
increases in optic nerve volume and proliferation, as well as
microglia and T-cell inﬁltration, beginning after 6 weeks of age8,9.
Moreover, the tumor-associated microglia express high levels of
Ccl5, a growth factor both necessary and sufﬁcient to drive Nf1optic glioma formation and continued growth10,11. Germane to
the pathobiology of inﬂammatory disease, inﬁltrating T cells in
the optic nerve produce Ccl4, which in turn stimulates microglia
to produce Ccl5 through activation of the NFκB signaling
pathway12. Moreover, T cell entry and activation are required for
Nf1-optic glioma growth in mice, and murine optic glioma stem
cells do not form tumors in T cell-deﬁcient mice13. As such,
Nf1OPG mice provide a tractable genetic platform to elucidate the
molecular and cellular mechanisms responsible for the reduced
incidence of brain tumors in children with a T cell-mediated
disease like asthma. Herein, we establish a mechanistic link
between asthma and gliomagenesis by demonstrating that asthma
induces decorin expression in T cells to reduce microglia support
of Nf1 optic glioma growth.
Results
Asthma induction inhibits Nf1OPG formation. To determine
whether experimental asthma induction reduces murine glioma
formation and growth in vivo, Nf1OPG mice were initially treated
with ovalbumin (OVA) or house dust mite (HDM) between 4 and
6 weeks of age and euthanized at 12 weeks of age when optic
gliomas are evident in >95% of mice (Fig. 1a). Experimental
asthma induction was conﬁrmed by H&E staining of lung tissue,
demonstrating inﬁltration of immune cells in peribronchiolar
locations, consistent with submucosal inﬂammation after OVA
or HDM challenge conditions compared to PBS controls
(Supplementary Fig. 1a). In addition, there were PAS+ airway
epithelial cells with morphology consistent with goblet cells, as
well as increased serum IgE in OVA-and HDM-treated mice
(Supplementary Fig. 1b, c). At 12 weeks of age, the optic nerves of
OVA- and HDM-treated Nf1OPG mice exhibited reduced
volumes (Fig. 1b) and proliferation (%Ki67+ cells; Fig. 1c),
without changes in microglia (%Iba1+ cells, Fig. 1c) or T cell
(CD3+ cells/nerve) (Fig. 1c) content. Importantly, this decrease in
optic nerve volume and proliferation was also observed at
24 weeks (18 weeks after asthma induction) (Fig. 1d–f), demonstrating a durable effect on gliomagenesis.
Interestingly, optic nerve volumes and proliferation did not
return to wild-type (WT) levels following asthma induction. Since
Nf1OPG mice, like patients with NF1-OPG, are heterozygous for a
germline Nf1 gene mutation in every non-neoplastic cell in their
bodies, we analyzed the optic nerves of mice with a germline Nf1
mutation (Nf1+/− mice). These Nf1+/− mice have increased optic
nerve volumes by direct measurements (Supplementary Fig. 2a, b)
and increased optic nerve areas by magnetic resonance imaging
(Supplementary Fig. 2c), similar to some patients with NF1
2

(Supplementary Fig. 2d)14. In addition, Nf1+/− mouse optic
nerves had increased microglia content (%Iba1+ cells; Supplementary Fig. 2e), but no change in proliferation (%Ki67+ cells;
Supplementary Fig. 2f) or T cell content (CD3+ cells; Supplementary Fig. 2g) relative to WT mice, thus providing a clear
separation of mice with optic gliomas (Supplementary Fig. 2h, i).
In this regard, OVA- and HDM-mediated asthma induction
reduces optic nerve volumes and proliferation to levels comparable to Nf1+/− mice (Supplementary Fig. 2j, k), thus establishing
that asthma blocks optic glioma formation.
Asthma reduces Nf1OPG Ccl5, but not Ccl4, levels. Prior studies
using Nf1OPG mice revealed that optic glioma progression and
maintenance requires T cells and microglia. In this manner,
T cells are activated by Nf1-mutant neurons through the production of Ccl4 that stimulates microglia to produce Ccl5 (Supplementary Fig. 3a), the critical growth factor required for Nf1optic glioma formation and continued growth10–12. To establish
where T cells are activated to express Ccl4, we analyzed Ccl4 RNA
expression in the blood, optic nerves, and draining cervical lymph
nodes of Nf1OPG mice (Fig. 2a, b). Consistent with our previous
ﬁndings that Nf1+/− neurons (retinal ganglion cells) stimulate
T cells to produce Ccl4, the highest levels of Ccl4 were observed
in the optic nerves (Fig. 2b).
Next, to determine whether experimental asthma attenuates
the increase in Ccl4 and Ccl5 expression observed in the optic
nerves of Nf1OPG mice at 12 (Fig. 2c and Supplementary Fig. 3b,
c) and 24 (Supplementary Fig. 3d, e) weeks of age, quantitative
real-time PCR was performed. No change in Ccl4 expression at
either 12 (Fig. 2d) or 24 (Supplementary Fig. 3f) weeks of age
were observed, indicating that OVA and HDM treatment does
not affect T cell Ccl4 production. In striking contrast, Ccl5
expression was reduced in the optic nerves of Nf1OPG mice
following OVA and HDM treatment at 12 (Fig. 2e) and 24
(Supplementary Fig. 3g) weeks of age. As expected, Ccl4 levels
were increased in the draining cervical lymph nodes of Nf1OPG
mice relative to WT controls (Fig. 2f); however, Ccl4 expression
was unchanged following OVA and HDM exposure (Fig. 2g).
Importantly, OVA or HDM treatment does not induce a switch
between conventional microglia phenotypes (M1 and M2)
(Supplementary Fig. 3h–l). The ﬁndings reveal that experimental
asthma induction impairs microglia Ccl5 support of optic glioma
formation and growth without altering T-cell Ccl4 expression.
Asthma reduces T cell induction of Ccl5 in microglia. T cell
Ccl4 production in Nf1OPG mice results from either T cell activation (Supplementary Fig. 4a, b) or Nf1-mutant neuron production of the pleiotrophin family member, midkine (Mdk), in
the setting of Nf1-OPG (Fig. 3a)12. Consistent with unchanged
T cell Ccl4 levels following experimental asthma induction, Mdk
levels were similar in OVA- and HDM-treated Nf1OPG mice
relative to controls (Fig. 3b), and Mdk does not induce Ccl5
production in microglia (Supplementary Fig. 4c). In addition,
naive T cells from PBS-treated (controls) and OVA-treated
Nf1OPG mice responded similarly to Mdk stimulation, producing
equivalent levels of Ccl4 (Fig. 3c).
Since there were no changes in MDK expression, we
then sought to determine whether the impaired microglia Ccl5
production resulted from other potential changes in the immune
microenvironment of Nf1-optic gliomas. First, it is conceivable
that experimental asthma induction alters T cell population
inﬁltration into the optic nerves. Previously, we demonstrated
that CD8+ T cells predominate in Nf1-optic gliomas (Supplementary Fig. 4d)12, which was unaffected in Nf1OPG mice
following either OVA or HDM treatment (Fig. 3d, e). In addition,
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no Foxp3+ cells (Tregs) were observed in optic gliomas from Nf1OPG mice treated with PBS, HDM, or OVA (Supplementary
Fig. 4e). Second, it is possible that known suppressors of
microglia function, like TGFβ15, or other inﬂammatory
mediators16–18 induced by asthma could be responsible. Treatment
of microglia with either TGFβ alone or in combination with Ccl4

P<0.0001 P<0.0001
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had no effect on Ccl5 expression (Supplementary Fig. 4f). While IL3, but not IL-4 or IL-5, was induced in T cells following OVA
treatment (Supplementary Fig. 4g–i), IL-3 treatment had no effect
on either T cell Ccl4 or microglia Ccl5 expression (Supplementary
Fig. 4j, k). Third, asthma induction could increase peripheral
macrophage inﬁltration; however, no change in Tmem119+ cell
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Fig. 1 Asthma induction inhibits Nf1OPG formation. a Schematic representation of the treatments used to induce asthma in Nf1OPG mice. Nf1OPG mice were
treated between 4 and 6 weeks of age with either OVA or HDM, while control Nf1OPG mice received PBS only (vehicle). Isolated optic nerves were
analyzed at 12 weeks of age. OVA and HDM treatments reduced (b) optic nerve volumes (WT, n = 6; PBS, n = 14; OVA, n = 6; HDM, n = 8) and (c)
percentage of proliferating (%Ki67+) tumor cells within the optic nerves of Nf1OPG mice relative to the vehicle-treated groups (WT, n = 6; PBS, n = 8;
OVA, n = 8; HDM, n = 9). No difference in microglia (%Iba1+ cells) or T cell (CD3+ cells) content were observed between OVA- or HDM-treated mice
and their respective controls. Reduced optic nerve volumes (e) and proliferation (%Ki67+ cells; f) were also observed at 24 weeks of age after OVA and
HDM treatment (d) between 4 and 6 weeks of age (WT, n = 6; PBS, n = 13; OVA, n = 8; HDM, n = 7). Data are presented as the means ± SEM. c, f Scale
bars, 40 µm. One-way ANOVA with Bonferroni post hoc correction. Exact P values are indicated within each panel (ns, not signiﬁcant). From left to right in
each panel: b P < 0.0001, P < 0.0001, P < 0.0003; c P = 0.0001, ns; e P < 0.0001, P = 0.0040, P = 0.0008; f P < 0.0001, P < 0.0001, P < 0.0001, ns,
P < 0.0001, ns.

(microglia) content was observed following OVA or HDM
treatment (Supplementary Fig. 4l). Moreover, splenic macrophages
fail to induce Ccl5 expression following Ccl4 treatment (Supplementary Fig. 4m). Similarly, OVA and HDM treatments had no
effect on other functions of microglia, such as phagocytosis and
viability (Supplementary Fig. 4n, o).
To test whether T cells from Nf1OPG mice exposed to OVA or
HDM could induce Ccl5 expression in microglia, we incubated
naive microglia with antibody-mediated activated T cell-conditioned medium (TCM) from OVA- or HDM-treated Nf1OPG
mice. Consistent with the whole tissue results demonstrating
reduced Ccl5 expression in the optic nerves of Nf1OPG mice
following OVA or HDM treatment, CD3+ TCM from both OVA
(Fig. 3f) and HDM (Fig. 3g) mice reduced microglia Ccl5
expression. Moreover, this TCM attenuation of Ccl5 was observed
in both CD4+ and CD8+ T cell populations following
experimental asthma induction in Nf1OPG mice (Fig. 3h, i).
Asthma induces T cell decorin expression to inhibit microglia
Ccl5 production. Since T cell Ccl4 levels were not reduced by
experimental asthma induction, we hypothesized that OVA- and
HDM-treated Nf1OPG mouse T cells might produce an inhibitor
of microglia Ccl5 production. To identify this inhibitor, we performed bulk RNA sequencing on isolated spleen CD3+ T cells
from Nf1OPG mice treated with PBS (control) or OVA (asthma
induction) (Fig. 4a and Supplementary Fig. 5a, b). Following ﬁltering of differentially expressed transcripts (P values ≤ 0.01, false
discovery rate ≤ 0.05, and log fold change ≥ 5), only one of the top
20 differentially expressed genes was predicted to be secreted
(Fig. 4b). This gene, decorin (Dcn), is a member of the small
leucine-rich proteoglycans (SLRPs)19, originally identiﬁed as a
collagen-binding protein20. Importantly, loss of decorin attenuates asthma in mice21, and OVA treatment of Dcn-deﬁcient mice
results in diminished lung pathology relative to WT mice22.
As predicted by the RNA sequencing results, Dcn RNA
expression was increased in CD3+ T cells from the spleen
(Supplementary Fig. 5c–e), cervical lymph nodes (Supplementary
Fig. 5f–h), and optic nerve (Supplementary Fig. 5i–k) of OVAand HDM-treated Nf1OPG mice. Consistent with the ability of
both CD4+ and CD8+ TCM to suppress microglia Ccl5
expression, both CD4+ and CD8+ splenic T cells from OVAtreated Nf1OPG mice exhibited elevated Dcn levels relative to
control PBS-treated mice (Fig. 4c). Relevant to the human
condition, DCN expression was also increased in CD4+ and
CD8+ T cells from patients with non-steroid-dependent asthma
relative to healthy controls (GSE31773; Fig. 4d).
With similar levels of decorin (Dcn) RNA expression in the
blood, optic nerves, and draining cervical lymph nodes of Nf1OPG
mice (Fig. 4e), we next wanted to determine whether decorin
could directly suppress microglia Ccl5 production. Decorin
protein levels were measured in the T cell-conditioned medium
(TCM) from OVA-treated Nf1OPG mouse CD3+ T cells relative
to their PBS-treated counterparts (Fig. 4f).
4

Using the concentration (800 pg/ml) of decorin detected in
OVA-treated Nf1OPG mouse CD3+ TCM, we found that
microglia Ccl5 production was reduced to 400 pg/ml (40%
decrease; Fig. 5a)—levels previously shown not to increase Nf1
mouse optic glioma stem cell growth in vitro12. To further
explore the direct effect of decorin on microglia Ccl5 production,
we quantiﬁed Ccl5 expression in primary microglia in response to
Ccl4 exposure over a range of decorin concentrations in vitro
(Fig. 5b). In contrast, other members of the SLRP family,
speciﬁcally biglycan (Bgn), were not induced in OVA-treated
Nf1OPG mice relative to PBS controls (Supplementary Fig. 6a),
and biglycan did not reduce microglia Ccl5 production
(Supplementary Fig. 6b). Taken together, these results demonstrate that T cells from Nf1OPG mice treated with HDM or OVA
produce decorin, which impairs the ability of T cells to stimulate
microglia, thus interfering with a tumor supportive microenvironment for murine Nf1-optic glioma formation.
Since the receptors for Ccl4 (Ccr5 and Ccr8) are both
expressed in microglia, we sought to determine which receptor
might be responsible for decorin-mediated suppression of Ccl4
induction of microglia Ccl5. While decorin (DCN) treatment
reduced microglia Ccl5 production, the addition of a Ccr8
inhibitor (MCV) had no further effect in suppressing microglia
Ccl5 production. In contrast, the addition of a Ccr5 inhibitor
(AZ058) further reduced activated T cell media-induced microglia Ccl5 levels (Fig. 5c). Based on these results, we conclude that
decorin binds to the Ccr8 receptor to reduce microglia Ccl5
production (Fig. 5d).
To demonstrate that decorin is sufﬁcient to block optic glioma
formation, Nf1OPG mice were treated with decorin (1 mg/ml) from
4 to 6 weeks of age, and then analyzed at 12 weeks of age (Fig. 5e).
As observed in the experimental models of asthma (OVA and
HDM induction) where decorin expression was induced in T cells,
decorin treatment of Nf1OPG mice reduced tumor proliferation (%
Ki67+ cells), with no change in optic nerve volumes, microglia
(Iba1+ cells), or T cells (CD3+ cells) in vivo (Fig. 5f, g).
Decorin inhibits microglia Ccl5 production through NFκB
inhibition. Since T cell Ccl4 induction of microglia Ccl5 production is controlled by NFkB activation in microglia12, we
measured NFκB activation (IκBαSerine32 phosphorylation) in the
optic nerves of Nf1OPG mice relative to their WT counterparts.
While NFκB activation was higher in Nf1OPG mouse optic nerves
compared to WT controls (Fig. 6a), optic nerves from OVAtreated Nf1OPG mice had reduced NFκB activation in vivo
(Fig. 6b). Consistent with decorin suppression of Nf1OPG
microglia NFκB activation, the addition of decorin (800 pg/ml)
reduced microglia NFκB activation (Fig. 6c), p65-NFκB activation
(Ser536 phosphorylation; Fig. 6d), and p65-NFκB nuclear location
(Fig. 6e, f) following activated T cell-conditioned medium (TCM)
exposure in vitro. Similarly, both decorin (Supplementary Fig. 6c)
and NFkB inhibition (CAPE; Supplementary Fig. 6d) blocked
Ccl4 induction of microglia Ccl5 expression in vitro. In addition,
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Fig. 2 Asthma reduces Nf1OPG Ccl5, but not Ccl4, levels. a Schematic representation of the journey of T cells from the periphery (blood) into the optic
nerve and draining through the cervical lymph node. b Increased Ccl4 mRNA expression was observed in optic nerves (n = 4) of Nf1OPG mice relative to
blood (n = 5) and draining cervical lymph nodes (n = 5). One-way ANOVA with Bonferroni post hoc correction. c Schematic representation of the
interactions between T cells and microglia in the optic nerve and draining cervical lymph node. d No change in Ccl4 mRNA expression was found in the
optic nerves of Nf1OPG mice treated with OVA (n = 4) or HDM (n = 3) relative to vehicle-treated (n = 7) mice. One-way ANOVA with Bonferroni post hoc
correction. e Decreased optic nerve Ccl5 mRNA expression was observed in both OVA- (n = 4) and HDM- (n = 3) treated mice relative to PBS-treated
controls (n = 7). One-way ANOVA with Bonferroni post hoc correction. f While Ccl4 gene expression was increased in the cervical lymph nodes of Nf1OPG
mice relative to controls (WT, n = 3; Nf1OPG, n = 3), Two-tailed Student’s t test. (g) No change in cervical lymph node Ccl4 mRNA expression was observed
between OVA- or HDM-treated mice (OVA, n = 4; HDM, n = 3) relative to controls (n = 7). One-way ANOVA with Bonferroni post hoc correction. Data
are presented as the means ± SEM. Exact P values are indicated within each panel (ns, not signiﬁcant). From left to right in each panel: b P < 0.0001,
P = 0.0460; d ns, ns; e P = 0.0069, P = 0.0359; f P = 0.0058; g ns.

NFkB inhibition has no effect on microglia viability (Supplementary Fig. 6e).
Lastly, to directly demonstrate that NFκB activation is
necessary for Nf1-optic glioma formation, Nf1OPG mice were
treated with a commercial NFκB inhibitor (10 mg/kg CAPE) from
4 to 6 weeks of age, and analyzed at 12 weeks of age (Fig. 6g).
Similar to both decorin-treated and OVA/HDM-induced Nf1OPG
mice, NFκB inhibitor (CAPE) treatment blocked tumor formation (optic nerve volumes, Fig. 6h; tumor proliferation, %Ki67+

cells, Fig. 6i). To demonstrate that decorin suppresses T-cellmediated microglia production of CCL5 by inhibiting NFκB
activation, we show that NFκB inhibition reduces Nf1OPG Ccl5
expression (Fig. 6j). However, in contrast to the decorin results,
NFκB inhibitor treatment also reduced microglia (%Iba1+ cells)
and T-cell (CD3+) content within the optic nerves of Nf1OPG
mice relative to the vehicle-treated groups (Fig. 6i), likely
reﬂecting the effect of NFκB inhibition on microglia and T cell
migration23,24.
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induced lower levels of microglial Ccl5 relative to PBS-treated Nf1OPG mice. Two-tailed Student’s t test. Similar reductions of Ccl5 expression were observed
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e P < 0.0001, P = 0.0022, P = 0.0011; f P = 0.0008; g P = 0.0015; h P = 0.0186, P = 0.0054; i P = 0.0224, P = 0.0007.

Discussion
Collectively, the ﬁndings presented in this report suggest a model
in which brain cancer risk is modiﬁed by alterations in circulating
T cell function (Fig. 6k), speciﬁcally by interfering with immune
cell (T lymphocyte-microglia) communication critical for the
establishment of a microenvironment supportive of glioma
growth. In this manner, we provide a mechanistic explanation for
the reported epidemiological risk association between asthma and
a reduced incidence of brain tumors in children with and without
NF125–27. Second, while allergen-induced asthma is typically
linked to CD4+ T cell responses28, the majority of the T cells in
the murine Nf1OPG tumors are CD8+ T cells9,12. Since CD8+
T cells also have complementary roles in asthma and autoimmune conditions29–31 and both murine and human CD4+ and
CD8+ T cells both exhibit increased decorin expression in the
setting of asthma, future studies will be required to deﬁne the
individual contributions of each T cell population to the suppression of microglia-mediated optic gliomagenesis. Third, the
6

discovery that decorin, an SLRP critical for experimental asthma
induction in mice and elevated in patients with asthma, has an
opposing role in glioma biology, raises the intriguing possibility
that speciﬁc molecules important for causing systemic inﬂammatory and autoimmune diseases have different effects in the
setting of brain cell axis function. In asthma, decorin potentiates
IFNγ activity32,33, such that decorin-deﬁcient mice have reduced
lung tissue inﬂammation21, while in cancer, it has anti-oncogenic
properties, including the prevention of metastatic spread and
angiogenesis34–36. While the mechanism underlying decorin
suppression of NFκB activity in response to CCL4 engagement of
its cognate G protein-coupled receptor, CCR512 remains to be
elucidated, decorin functions in other cell types to block receptor
tyrosine kinase (insulin-like growth factor receptor-1, c-MET,
and epidermal growth factor receptor) signaling37–39. Lastly, the
ﬁndings described in this report add to a growing literature
implicating T lymphocyte in brain function, including
learning40,41 social behavior42,43 and neurodegeneration in the
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Fig. 4 Asthma-induced T cell decorin inhibits microglia Ccl5 level. a Heatmap showing differential gene expression in CD3+ T cells from PBS- versus
OVA-treated Nf1OPG mice (n = 5). b Top transcripts increased in T cells from OVA-, relative to PBS-treated, Nf1OPG mice calculated with DESeq2 were
ﬁltered for only those genes with P values ≤ 0.01, false discovery rates ≤ 0.05, and log fold changes greater or equal to ±5. P values, false discovery rate
(FDR), and fold changes are shown in a tabular form. c Increased Dcn gene expression was detected in both splenic CD4+ and CD8+ T cells from OVAtreated Nf1OPG mice relative to PBS-treated controls. Data are presented as the means ± SEM of n = 3 independent biological samples. d DCN RNA
expression was increased in CD4+ and CD8+ T cells from patients with non-steroid-dependent asthma (n = 4) relative to healthy controls (n = 6;
GSE31773). Two-tailed Student’s t test. Exact p values are indicated within each panel. e Similar levels of Dcn mRNA expression were observed in T cells
from the blood (n = 5), optic nerves (n = 5), and cervical lymph nodes (n = 5) in Nf1OPG mice treated with OVA. Data are presented as the means ± SEM of
n = 5 independent biological samples. One-way ANOVA with Bonferroni post hoc correction. f Increased Dcn levels were detected in CD3+ T cellconditioned medium (TCM) from OVA-treated Nf1OPG mice relative to PBS-treated controls by ELISA. Two-tailed Student’s t test. Exact P values are
indicated within the panel. Data are presented as the means ± SEM of n = 3 independent biological samples. From left to right in each panel: c P = 0.0006,
P = 0.0002; d P = 0.0007, P = 0.0032; e ns; f P = 0.0003.

setting of neuronal injury44,45. In this manner, it is conceivable
that other systemic conditions involving T lymphocytes, such as
eczema26,46,47, rheumatoid arthritis48,49, and diabetes50,51, may
similarly impact gliomagenesis through overlapping or related
mechanisms. Deﬁning the molecular etiologies underlying how
these T cell-mediated systemic conditions inﬂuence brain function and nervous system disease pathogenesis may also reveal

unique immunomodulatory treatment strategies for neurological
disorders.
Methods

Mice. Nf1ﬂox/mut; GFAP-Cre (Nf1OPG) mice (Nf1+/− mice with somatic Nf1 gene
inactivation in neuroglial progenitors at E15.5), Nf1+/− mice (neomycin sequence
insertion within exon 31 of the murine Nf1 gene), and Nf1ﬂox/ﬂox mice (controls)6,12
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were used in accordance with an approved Animal Studies Committee protocol at
Washington University in St. Louis. All mice used in these experiments were
maintained on a strict C57BL/6 background and were housed in a speciﬁc
pathogen-free barrier facility with controlled light-dark cycles (12:12 h) and ad
libitum access to food and water.
Experimental mouse asthma models. Two different allergen challenges were used
to induce experimental asthma in Nf1OPG mice. For the ovalbumin (OVA)-induced
asthma model, mice were intraperitoneally injected with 0.5 mL of chicken egg
ovalbumin (16 μg/mL) in aluminum hydroxide (2 mg/mL) weekly for two weeks
(days −14 and −7), as previously reported52. On day 0, mice were anesthetized
8
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with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg).
After a desired level of anesthesia was achieved and veriﬁed by loss of the toe pinch
reﬂex, 30 μl of ovalbumin in PBS was administered intranasally. Mice received a
total of four intranasal doses of ovalbumin (2 doses, 12 h apart on day 0; 1 dose on
day 1; and 1 dose on day 2). For the house dust mite (HDM)-induced asthma
model53,54, mice were anesthetized as described above and one dose of 1 µg HDM
in PBS was given intratracheally (day 0). From days 6 to 10, mice were anesthetized
and 40 μl of HDM solution (10 μg/ml) in PBS was administered intranasally. Optic
nerve and lungs were harvested at 12, 24 weeks of age. Lungs were analyzed for
asthma induction, while optic nerves were used for Iba1, Ki67, CD3, CD4, and CD8
analysis by counting the number of immunoreactive cells by
immunohistochemistry.
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Fig. 5 Decorin inhibits Nf1-OPG formation. a Decorin (800 pg/ml) attenuated activated TCM (act-Tm)-mediated microglia Ccl5 production (n = 3). Twotailed Student’s t test. Exact P values are indicated within each panel (ns, not signiﬁcant). b Decorin reduces microglia Ccl5 production in response to Ccl4
exposure (6 ng/ml) over a physiologic dose range in vitro (n = 4). One-way ANOVA with Bonferroni post hoc correction. Data are presented as the
means ± SEM. c TCM (activated T cell-conditioned media) induced microglial Ccl5 production was signiﬁcantly attenuated by decorin. The addition of Dcn
with CCR5 has the greatest inhibition similar to the combination of CCR5 and CCR8 inhibitors (n = 6). One-way ANOVA with Bonferroni post hoc
correction. Data are presented as the means ± SEM. d Schematic representation of decorin binding to the CCR8 receptor on microglia, culminating is
reduced microglial Ccl5 production by inhibiting NFκB activation. e Schematic representation of decorin treatment of Nf1OPG mice. Nf1OPG mice were
treated between 4 and 6 weeks of age with decorin, while control Nf1OPG mice received PBS only. Isolated optic nerves were analyzed at 12 weeks of age.
f Decorin treatment has no change on optic nerve volume, but (g) decreased proliferation (%Ki67+ cells) of Nf1OPG mice relative to the vehicle-treated
Nf1OPG controls (PBS, n = 8, Decorin, n = 8). No difference in microglia (%Iba1+ cells) or T cell (CD3+ cells) content was observed between decorintreated mice and their respective controls. Two-tailed Student’s t test (ns, not signiﬁcant). g Scale bars, 40 µm. From left to right in each panel:
a P = 0.0134, b P < 0.0001, P = 0.0035; c P < 0.0001, ns, P = 0.0086, ns; f ns; g P = 0.0010, ns, ns.

Mouse treatments. Four-week-old Nf1OPG mice were treated with 10 mg/kg
NFκB inhibitor (NFκB-IN; Caffeic acid phenethyl ester, Fisher Scientiﬁc, 274310)
or 1 mg/ml Decorin (R&D System 1060-DE-100) intraperitoneally every other day
for 2 weeks between 4 and 6 weeks of age. Brains and optic nerves were harvested
when mice reached 12 weeks of age, and Iba1, Ki67, and CD3-positive cells were
analyzed by counting the number of cells showing a positive signal after
immunohistochemistry.
Optic nerve volume analysis. Micro-dissected optic nerves were photographed
using Leica DFC 3000 G camera. Measurements were performed using Image-J
software beginning at the chiasm (D0) and at 150 (D150), 300 (D300) and 450 µm
(D450) anterior to the chiasm to generate optic nerve volume estimates, as previously reported7. The volumes for regions 1, 2, and 3 calculated at the three
150 µm high truncated cones were combined using the diameter (D0, D150, D300,
and D450) values from each optic nerve measurement. The following equation was
used to calculate the total optic nerve volume:
V1 ¼

1
πhðD20 þ D0 D150 þ D2150 Þ
12

Human magnetic resonance imaging. T2-weighted axial magnetic resonance
images from patients managed at the St. Louis Children’s Hospital Neuroﬁbromatosis Clinical Program (D.H.G.) were de-identiﬁed. The MRI scans were deidentiﬁed images from children cared for at the St. Louis Children’s Hospital NF
Clinical Program. No IRB consent is required, as the use of anonymized human
samples is not considered human subjects research by the Washington
University IRB.
Mouse magnetic resonance imaging. Mice were intraperitoneally injected with
70 mM MnCl2 in 100 mM Bicine, pH 7.4 at 140 mg/Kg body weight (10x μL)
16–24 h before imaging. Mice were then subcutaneously injected with 0.5 mL 0.9%
saline to minimize magnesium toxicity, and half of the mouse cage was placed on a
medium heating pad setting. T1-weighted images (T1W) were collected as previously reported55. T1W were collected with 2D spin-echo (SEMS, at 4.7 T): TR/
TE, 300 ms/11 ms; matrix size, 128 × 128; FOV, 16 × 16 mm2; slice thickness,
0.5 mm; averages, 16 × 2 (10 × 2 min.). In addition, the 3D T1W were collected
using a gradient-echo sequence (GE3D): Matrix size, 128 × 128 × 128; FOV,
24 × 24 × 24 mm3; TR/TE, 4 ms/2 ms; Flip angle, 12°; averages, 8 (9 min). All image
data were zero-padded and applied with a Gaussian ﬁlter (Sigma 0.75) before
conversion to a NIfTI format for analysis.
Immunohistochemistry, H&E, and PAS staining. Nf1OPG mice were euthanized
and transcardially perfused with Ringer’s solution, followed by 4% paraformaldehyde (PFA). Optic nerves and lungs were harvested and processed for parafﬁn
embedding and sectioning in either the Ophthalmology (optic nerves) or Pulmonary Morphology (lungs) core facilities. H&E and PAS staining were performed
as previously reported8,12,52,53. Serial 4-μm parafﬁn sections of the optic nerve were
immunostained with the antibodies listed in Supplementary Table 1. Development
was performed using the Vectastain ABC kit (Vector Laboratories, PK4000), and
imaged for quantitation in Zeiss AxioScan-Z1 and Leica ICC50W microscope
using LAS EZ software.
T cell isolation. Mouse spleens were homogenized into single-cell suspensions by
digesting in PBS containing 0.1% BSA and 0.6% Na-citrate, washed, and incubated
with 120 Kunitz units of DNase I for 15 min following red blood cell lysis
(eBioscience, 00433357)12. Cells were then ﬁltered through a 30-µm cell strainer to
generate a single-cell suspension. CD4+ and CD8+ T cells were isolated using
CD8a (Miltenyi Biotec, 130-104-075) and CD4 (Miltenyi Biotec, 130-117-043)
T cell isolation kits, respectively. T cells were maintained at 2.5 × 106 cells/ml in
RPMI-1640 medium supplemented with 10% FBS and 1% P/S. T cells were activated using 1.25 µg/ml anti-mouse CD3 (Fisher Scientiﬁc, 16-0031-85) and 2 µg/ml

anti-mouse CD28 (Fisher Scientiﬁc, 16-0281-82) antibody treatment for 2d.
Recombinant mouse midkine (R&D Systems, 9760-MD-050) was added, and Ccl4
levels were quantitated by ELISA (R&D Systems, MMB00). Conditioned medium
was collected from activated T cells for chemokine assays and microglia co-culture
experiments. Cell viability was measured using a commercial WST-1 cell viability
assay (Millipore).
Microglia isolation. Microglia were isolated from mouse brains as previously
described12. Brieﬂy, mouse brains were perfused with D-PBS (Fisher Scientiﬁc,
14287072), and single-cell suspensions were generated using the multi-tissue dissociation kit (Miltenyi-130-110-201), as per the manufacturer’s protocol. The
resulting cells were maintained in minimal essential medium supplemented with
1 mM L-glutamine, 1 mM sodium pyruvate, 0.6% D-(+)-glucose, 1 ng/ml GM-CSF,
100 μg/ml P/S, and 10% FBS for 2 weeks. Microglia were separated from astrocytes
by shaking (200 g, 5 h, 37 °C) after 2 weeks. In total, 5 × 105 microglia were grown
in T cell-conditioned media (TCM) for 48 h8,9, followed Ccl5 (R&D Systems,
MMR00) and decorin (Abcam, ab155454) determinations by ELISA. Mouse
recombinant Decorin protein (R&D Systems, 1060-DE-100), AZ084(CCR8IN;
MedChemExpress, CAS No-929300-19-6), Maraviroc (CCR5IN; MedChemExpress, CAS no-376348-65-1) was added to the TCM microglia co-culture, and Ccl5
levels were quantiﬁed by ELISA. Mouse recombinant CCL4 (R&D Systems, 451MB-010/CF), Mouse recombinant Biglycan (R&D Systems, 8128-CM-050), Mouse
recombinant TGFβ1 (R&D Systems, 7666-MB-005), Caffeic acid phenethyl ester
(NFκB-IN; Fisher Scientiﬁc, 274310) was added to the Viability were added to the
microglia and Ccl5 levels quantiﬁed by ELISA. Viability was determined using
WST-1 assay reagent (Abcam, ab155902).
Phagocytosis assay. Phagocytosis was determined using green ﬂuorescent latex
beads (Sigma, L1030-1ML) pre-opsonized in fetal bovine serum (FBS) (1:5 ratio) for
1 h at 37 °C at a ratio of 1:5 before dilution to a ﬁnal concentration of 0.01% (v/v) and
0.05% (v/v) in DMEM. Puriﬁed microglia were plated at a density of 50,000 cells/cm2,
as previously reported11. After 24 h, the cells were incubated with ﬂuorescent latex
beads in FBS for 1 h at 37 °C, washed, and then ﬁxed in 4% PFA for 15 min. Microglia
were blocked prior to incubation with primary antibody (Iba1,1:200 Wako Chemicals
019-1794, Japan) overnight at 4 °C, washed, and then incubated with secondary
antibody for 1 h. Images were acquired on a Leica DFC3000G ﬂuorescent microscope
using a ×10 objective with associated Leica Application Suite X software. The number
of phagocytic cells with beads relative to the total number of cells was calculated and
expressed as a percentage: Ncell with beads/Ntotal.
RNA extraction and real-time qRT-PCR. RNA was isolated from cells and
transcardially perfused optic nerves using the NucleoSpin® RNA Plus kit (Takara740984.205), as per the manufacturer’s instructions. Total RNA was then reverse
transcribed into cDNA using the Applied Biosystems High-Capacity cDNA
Reverse Transcription Kit (#4374967), as per the manufacturer’s instructions. Realtime quantitative PCR (qPCR) was performed by TaqMan gene expression (Supplementary Table 2). ΔΔCT values were calculated using Gapdh as an internal
control.
RNA sequencing and analysis. RNA from PBS- and OVA-treated spleen CD3+
T cells was isolated and sequenced on an Illumina HiSeq platform. Base calls and
demultiplexing were performed with Illumina’s bcl2fastq software, and a custom
python demultiplexing program with a maximum of one mismatch in the indexing
read. The analysis was generated using Partek Flow software, v9.0. RNA-seq reads
were aligned to the Ensembl release 99 top-level assembly with STAR v2.6.1d. Gene
counts and isoform expression were derived from Ensembl output. Sequencing
performance was assessed for the total number of aligned reads, the total number
of uniquely aligned reads, and features detected56. Normalization size factors were
calculated for all gene counts by median ratio. Differential genetic analysis was then
performed using DESeq2 to analyze for differences between conditions57. Results
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for OVA samples compared separately with controls were ﬁltered for only those
genes with P values ≤ 0.01, false discovery rates ≤ 0.05, and log fold changes ≥ 5.
Human microarray analysis. Raw Affymetrix U133 Plus 2.0 microarray data were
obtained from the Gene Expression Omnibus (GSE31773) derived from samples of
circulating CD4+ and CD8+ T cells from non-severe asthma patients (perfect
control of their asthma with 0–1000 μg/d inhaled beclomethasone or an equivalent
dosage; n = 4; donors 1–4) and healthy control (n = 5; donors 1, 3, 4, 6, 8)
10

subjects58. The analysis was performed using Partek Flow software, v9.0. mRNA
was aligned to the Ensembl release 100 top-level assembly with STAR v2.7.3a. Gene
counts and isoform expression were derived from Ensembl output. Non-coding
RNA data were excluded from further analysis. Normalization size factors were
calculated for all gene counts by CPM to adjust for differences in library size. Genespeciﬁc analysis was performed using the lognormal with shrinkage model (limmatrend method) to analyze for differences between disease and cell-type conditions.
The GSA (gene-speciﬁc analysis) results were ﬁltered for the DCN gene. The cut-off
used for signiﬁcance was P value ≤ 0.05.

NATURE COMMUNICATIONS | (2021)12:7122 | https://doi.org/10.1038/s41467-021-27455-6 | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-27455-6

ARTICLE

Fig. 6 Decorin suppresses Nf1-OPG formation through microglia NFkB inhibition. a Nf1OPG mouse optic nerves (n = 3) have increased Iκbα
phosphorylation relative to WT mice (n = 3). b The increased Iκbα phosphorylation in PBS-treated Nf1OPG mouse optic nerves (n = 3) was reduced by
OVA treatment (n = 3). c Activated TCM (act-Tm) increased Iκbα phosphorylation in microglia, which was reduced following the addition of decorin
(800 pg/ml). d Decorin (800 pg/ml) blocks the increased p65-NFκB Ser536 phosphorylation induced by activated TCM (act-Tm) treatment (n = 3).
e Decorin (800 pg/ml) blocks the increased total p65-NFκB expression, (f) as well as the nuclear localization of p65-NFκB, induced by activated TCM
(act-Tm) treatment (n = 3). β-actin and HDAC are used as controls for total protein expression and the nuclear fractions, respectively. g Schematic
representation of the NFκB inhibitor treatment used. Nf1OPG mice were treated between 4 and 6 weeks of age with the CAPE NFκB inhibitor (n = 8),
whereas control Nf1OPG mice received PBS only (n = 8). Isolated optic nerves were analyzed at 12 weeks of age. h NFκB inhibitor treatment reduced optic
glioma volume and (i) proliferation (%Ki67+ cells), as well as microglia (%Iba1+ cells) and T-cell (CD3+) content within the optic nerves of Nf1OPG mice
relative to vehicle-treated controls. Two-tailed Student’s t test. j Reduced Ccl5 RNA expression was observed in the optic nerves from Nf1OPG mice treated
with the CAPE NFκB inhibitor (NFκB-IN) (n = 5). Two-tailed Student’s t test. k Proposed model of asthma-induced decorin suppression of the Nf1OPG
neuron-immune-cancer cell axis. Asthma induces T cell production of decorin, which reduces T cell Ccl4-mediated microglia Ccl5 expression through
inhibition of NFκB signaling. Data are presented as the means ± SEM. Exact P values are indicated within each panel. i Scale bars 40 µm. From left to right in
each panel: h P = 0.0288; i P = 0.0003, P = 0.0196, P = 0.0025; j P = 0.0018.

Western blotting. Total protein was extracted using RIPA buffer and quantiﬁed
using the Pierce BCA protein assay kit (Fisher scientiﬁc, PI23225). Subcellular
fractions were isolated following the manufacturer’s protocol (Thermo scientiﬁc
78840). In all, 40 µg of total protein lysate was separated in precast SDSpolyacrylamide gels by electrophoresis and transferred onto PVDF membranes,
followed by blocking and incubation with the indicated antibody (Supplementary
Table 1) overnight. Proteins were detected with IRDye-conjugated secondary
antibodies in LI-COR Odyssey Imaging system using Image Studio v5.2.
Statistical analysis. Data were analyzed using GraphPad Prism software. To
determine differences between two groups, two-tailed Student’s t test was used
whereas multiple comparisons were analyzed by one-way analysis of variance
(ANOVA) with Dunnett’s multiple comparisons test. Statistical signiﬁcance was set
at P ≤ 0.05. All experiments were independently repeated at least three times.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The RNA-seq data were deposited in GEO (Accession number 166551). The Raw
Affymetrix U133 Plus 2.0 microarray data used in this study are available in the GEO
database under accession code GSE31773. The remaining data are available within the
Article, Supplementary Information or Source Data ﬁle. Source data are provided with
this paper.
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